Leads Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 05-12-2024
- Paid Up Capital ₹ 4.00 M
as on 05-12-2024
- Company Age 17 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
as on 05-12-2024
- Revenue -32.02%
(FY 2021)
- Profit -120.19%
(FY 2021)
- Ebitda -25.94%
(FY 2021)
- Net Worth -0.65%
(FY 2021)
- Total Assets -6.51%
(FY 2021)
About Leads Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹2.00 M.
Prabha Bodapunti, Leelavathi Bodapunti, Samay Bodapunti, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233TG2007PTC054104
- Company No.
054104
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 May 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Leads Pharma Private Limited offer?
Leads Pharma Private Limited offers a wide range of products and services, including Vitamin Tablets & Capsules, Folic Acid Tablet, Industrial Air Conditioner & Devices, Industrial Cooling System, Nutraceuticals, Dietary Supplements, Anti Inflammatory Drugs, Women Care, Feminine Hygiene, Sexual Wellness.
Who are the key members and board of directors at Leads Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabha Bodapunti  | Director | 22-May-2007 | Current |
| Leelavathi Bodapunti | Director | 22-May-2007 | Current |
| Samay Bodapunti | Director | 04-Sep-2014 | Current |
| Sonika Bodapunti | Director | 04-Sep-2014 | Current |
Financial Performance and Corporate Structure Insights of Leads Pharma.
Leads Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 32.02% decrease. The company also saw a substantial fall in profitability, with a 120.19% decrease in profit. The company's net worth dipped by a decrease of 0.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Leads Pharma?
In 2021, Leads Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 29 Nov 2016 | ₹2.00 M | Open |
How Many Employees Work at Leads Pharma?
Unlock and access historical data on people associated with Leads Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Leads Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Leads Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
